NasdaqGS - Delayed Quote • USD
Viatris Inc. (VTRS)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:44 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
15,426,900.00
15,426,900.00
16,262,700.00
17,886,300.00
11,946,000.00
Cost of Revenue
8,988,300.00
8,988,300.00
9,765,700.00
12,310,800.00
8,149,300.00
Gross Profit
6,438,600.00
6,438,600.00
6,497,000.00
5,575,500.00
3,796,700.00
Operating Expense
5,455,300.00
5,455,300.00
4,841,300.00
5,210,200.00
3,857,200.00
Operating Income
983,300.00
983,300.00
1,655,700.00
365,300.00
-60,500.00
Net Non Operating Interest Income Expense
-573,100.00
-573,100.00
-592,400.00
-636,200.00
-497,800.00
Other Income Expense
-207,300.00
-207,300.00
1,749,900.00
-393,500.00
-162,900.00
Pretax Income
202,900.00
202,900.00
2,813,200.00
-664,400.00
-721,200.00
Tax Provision
148,200.00
148,200.00
734,600.00
604,700.00
-51,300.00
Net Income Common Stockholders
54,700.00
54,700.00
2,078,600.00
-1,269,100.00
-669,900.00
Diluted NI Available to Com Stockholders
54,700.00
54,700.00
2,078,600.00
-1,269,100.00
-669,900.00
Basic EPS
1.51
0.05
1.71
-1.05
-1.11
Diluted EPS
1.51
0.05
1.71
-1.05
-1.11
Basic Average Shares
1,203,550.00
1,200,300.00
1,212,100.00
1,208,800.00
601,200.00
Diluted Average Shares
1,209,525.00
1,206,900.00
1,217,400.00
1,208,800.00
601,200.00
Total Operating Income as Reported
766,200.00
766,200.00
1,614,900.00
-34,000.00
-210,800.00
Total Expenses
14,443,600.00
14,443,600.00
14,607,000.00
17,521,000.00
12,006,500.00
Net Income from Continuing & Discontinued Operation
54,700.00
54,700.00
2,078,600.00
-1,269,100.00
-669,900.00
Normalized Income
226,209.00
226,209.00
2,108,746.05
-977,611.00
-530,271.30
Interest Expense
573,100.00
573,100.00
592,400.00
636,200.00
497,800.00
Net Interest Income
-573,100.00
-573,100.00
-592,400.00
-636,200.00
-497,800.00
EBIT
776,000.00
776,000.00
3,405,600.00
-28,200.00
-223,400.00
EBITDA
3,516,500.00
3,516,500.00
6,433,200.00
4,478,300.00
1,992,700.00
Reconciled Cost of Revenue
8,988,300.00
8,988,300.00
9,765,700.00
12,310,800.00
8,149,300.00
Reconciled Depreciation
2,740,500.00
2,740,500.00
3,027,600.00
4,506,500.00
2,216,100.00
Net Income from Continuing Operation Net Minority Interest
54,700.00
54,700.00
2,078,600.00
-1,269,100.00
-669,900.00
Total Unusual Items Excluding Goodwill
-217,100.00
-217,100.00
-40,800.00
-399,300.00
-150,300.00
Total Unusual Items
-217,100.00
-217,100.00
-40,800.00
-399,300.00
-150,300.00
Normalized EBITDA
3,733,600.00
3,733,600.00
6,474,000.00
4,877,600.00
2,143,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-45,591.00
-45,591.00
-10,653.95
-107,811.00
-10,671.30
12/31/2020 - 3/17/1980
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TEVA Teva Pharmaceutical Industries Limited
13.81
+4.23%
ELAN Elanco Animal Health Incorporated
13.26
+1.69%
HLN Haleon plc
8.45
+0.60%
ZTS Zoetis Inc.
158.42
+3.30%
TAK Takeda Pharmaceutical Company Limited
13.03
-0.31%
BHC Bausch Health Companies Inc.
8.71
+1.04%
ESPR Esperion Therapeutics, Inc.
1.9000
-4.52%
DVAX Dynavax Technologies Corporation
11.21
+0.36%
EOLS Evolus, Inc.
11.43
-0.26%
DCPH Deciphera Pharmaceuticals, Inc.
14.65
+3.31%